Washington, DC | May 2026. ImmunoPDT presented at the American Urological Association’s (AUA) Innovation Nexus Forum in Washington, DC. Director Mark Lawrence presented the company’s experience in treating prostate cancer while seeking to minimise further harm to patients. The response, the company says, has added real momentum to the program.
News
For immediate release
Washington, D.C. | 14 May 2026. ImmunoPDT today announced the appointment of Dr William J Lynch (Bill Lynch), MB BS, MMed, MSc, FRACS, FRCSEd(Hon), as Principal Investigator of its clinical program for early-stage prostate cancer. Dr Lynch is President of the Société Internationale d’Urologie (SIU) and Clinical Associate Professor of Urology at Macquarie University.
For immediate release
Melbourne, Australia | 3 February 2026. ImmunoPDT has been selected to present at the American Urological Association’s (AUA) 2026 Innovation Nexus Forum in Washington, DC on 14 May 2026. The selection features ImmunoPDT’s lead program, Immuno1, an investigational, orally administered photodynamic therapy (PDT) agent developed for early-stage prostate cancer.
The National Institute of Integrative Medicine (NIIM) in Melbourne ran a three-month Prostate Cancer Photodynamic Therapy (PDT) Study, assessing photodynamic therapy in men with prostate cancer.